Navigation Links
Lexicon To Present At The Jefferies Global Healthcare Conference
Date:5/31/2013

THE WOODLANDS, Texas, May 31, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Arthur Sands , M.D., Ph.D., president and chief executive officer, will present at the Jefferies Global Healthcare Conference on Tuesday, June 4, at 9:00 AM ET in New York City. Dr. Sands will provide an overview of Lexicon's clinical development programs and milestones.

A webcast of the presentation will be available through Lexicon's website at www.lexpharma.com. An archived version of the presentation will be available at www.lexpharma.com until July 4, 2013.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has multiple programs in clinical development for diabetes, irritable bowel syndrome, carcinoid syndrome and other indications, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forwar
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Lexicon to Provide First Quarter 2012 Financial Results
2. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
3. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
4. Lexicon Pharmaceuticals to present at the Jefferies 2012 Global Healthcare Conference
5. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
6. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
7. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
8. Lexicon to Provide Second Quarter 2012 Financial Results
9. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 Second Quarter Results
10. Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
11. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... SAN DIEGO , Oct. 20, 2014 /PRNewswire/ ... development of therapeutic antibodies, today announced the appointment ... Development Officer. Dr. Londei will lead the preclinical ... "We are pleased to welcome ... Hamza Suria , President and Chief Executive ...
(Date:10/20/2014)... , Oct. 20, 2014 Lpath, ... leader in bioactive lipid-targeted therapeutics, received official notification from ... been granted another key patent supporting its iSONEP™ ... issued patent, European patent No. 2087002, claims compositions ... in Lpath,s two lead compounds, iSONEP and ASONEP. ...
(Date:10/20/2014)... , Oct. 20, 2014   Mary,s Medicinals ... for Caring, is a 4-Star Sponsor of Operation ... Veterans with unique products, programs and services to assist ... freedom. Key Facts: , An ... is a safe and effective treatment for pain, Post-traumatic ...
Breaking Medicine Technology:AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 2Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 3
... Calif. , June 30 Xoft, the ... that Hoag Breast Care Center of Hoag Memorial Hospital ... installed an Axxent® Electronic Brachytherapy, eBx™ System to support ... as part of its progressive, comprehensive approach to breast ...
... WILMINGTON, Del. , June 29 AstraZeneca (NYSE: ... District Court, District of Delaware , has found that the substance patent ... ruling, the court found that no inequitable conduct was committed by any Shionogi ... reissued. , , , ...
Cached Medicine Technology:Hoag Breast Care Center Installs Xoft Electronic Brachytherapy System for IORT Program 2Hoag Breast Care Center Installs Xoft Electronic Brachytherapy System for IORT Program 3Hoag Breast Care Center Installs Xoft Electronic Brachytherapy System for IORT Program 4CRESTOR® Patent Upheld By US Court 2CRESTOR® Patent Upheld By US Court 3
(Date:10/20/2014)... Unveiled at the Sept. 18 board meeting, The Center ... hospital ROI on membership dues at 12.5. In other words, ... in value to member hospitals. The calculation used to determine ... , “This is the first time we’ve actually been ... methodology is really sound,” said Bill Ryan , president ...
(Date:10/20/2014)... Do you ever feel difficulty in ... wonderful app Metassessor for teachers, specialists and parents. SIMpalm, ... its client “Intervention Development LLC” to launch Metassessor App ... for iOS 4.3 or later and is Compatible with ... for iPhone 5. It is now available on Apple ...
(Date:10/19/2014)... Dr. Babatunde Osotimehin, Executive Director of ... a ceasefire agreement that is expected to lead to ... were kidnapped from the north-eastern Nigerian town of Chibok—the ... enough, and it is high time they are returned ... , "We owe it to these girls to positively ...
(Date:10/19/2014)... Recently, Fancyflyingfox.com, an innovative company that ... announced its latest designs of 2014 mother of ... elegant outfits are offered with big discounts, up to ... October 30 can enjoy this special offer. , ... it has become one of the leading brands in ...
(Date:10/19/2014)... 19, 2014 (HealthDay News) -- New stem cell-based research ... to new treatments, a new study suggests. Scientists ... intestinal tissue in a lab dish. They then transplanted ... studying intestinal disorders, according to the researchers. "This ... and conditions that can cause intestinal failure, from genetic ...
Breaking Medicine News(10 mins):Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2Health News:Scientists Grow, Implant Human Intestinal Tissue in Mice 2
... detection system finds cavities before X-rays allowing, ... filling required, TORONTO, July 3 /PRNewswire/ - ... its breakthrough technology which,detects and monitors the early ... x-rays. It reduces the number of invasive and ...
... Utah, July 3 Nu Skin Enterprises, Inc.,(NYSE: ... presenting at the,Oppenheimer Consumer Growth Conference in Boston on ... webcast live beginning at 2:55 p.m.,(EST). Those wishing to ... Nu Skin Enterprises, website, at, http://www.nuskinenterprises.com . The archive ...
... DETROIT, July 2 The Michigan Attorney General announced,on ... Cross Blue Shield of,Michigan challenging a capital transaction between ... taken the position that BCBSM is not,authorized by Public ... in fact, Accident Fund obtained prior regulatory approval for ...
... General Hospital (MGH) investigators have shown that an MGH-developed, ... the bloodstream can be used to determine the genetic ... for targeted treatment and monitoring genetic changes that occur ... called the CTC-chip will appear in the July 24 ...
... light of today,s,announcement that Attorney General Mike Cox is ... the Coalition for a Fair and,Competitive Insurance Market is ... Blue Cross Blue Shield of Michigan (BCBSM) to use ... and insurance., "We were confident when we raised ...
... individual patients, study says , , WEDNESDAY, July 2 (HealthDay News) ... cells in the blood of lung cancer patients may make ... the genetic "signature" of particular tumors but to monitor changes ... think this is key to personalized medicine," said Dr. Daniel ...
Cached Medicine News:Health News:Breakthrough Technology That Will Revolutionize the Treatment of Tooth Decay 2Health News:Breakthrough Technology That Will Revolutionize the Treatment of Tooth Decay 3Health News:Circulating tumor cells can reveal genetic signature of dangerous lung cancers 2Health News:Circulating tumor cells can reveal genetic signature of dangerous lung cancers 3Health News:Coalition Calls on MI Legislature to Abandon Blue Cross Legislation 2Health News:Circulating Tumor Cells Reveal Insights Into Lung Cancers 2Health News:Circulating Tumor Cells Reveal Insights Into Lung Cancers 3
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
... Hamilton is precision, ergonomics, and ... hand fatigue with soft non-slip, contoured ... with smooth, light plunger spring action ... and sterilization without the need for ...
This fixed-volume digital micropipet is used to accurately measure and transfer 20 microliters of solution....
... The Research Family includes fixed-volume, ... as the electronic Eppendorf Research pro ... button, these compact, high-performance pipettes have ... Optimally suited for use with original ...
Medicine Products: